The U.S. Food and Drug Administration (FDA) has announced major steps to make it faster and less costly to develop biosimilar medicines, lower-cost "generic" alternatives to biologic drugs used to treat serious and chronic diseases.
High expenditures for treating hepatic encephalopathy in people with end-stage liver disease were linked to worse patient adherence to therapy, according to research from the University of Minnesota Medical School and College of Pharmacy.